Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Proteome Sciences's Enterprise Value is €25.17 Mil.
Proteome Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-2.80 Mil. Therefore, Proteome Sciences's EV-to-EBIT ratio for today is -9.00.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Proteome Sciences's Enterprise Value is €25.17 Mil.
Proteome Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.80 Mil. Therefore, Proteome Sciences's EV-to-EBITDA ratio for today is -14.01.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Proteome Sciences's Enterprise Value is €25.17 Mil.
Proteome Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €5.84 Mil. Therefore, Proteome Sciences's EV-to-Revenue ratio for today is 4.31.
Proteome Sciences Enterprise Value Historical Data
The historical data trend for Proteome Sciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Proteome Sciences's Enterprise Value
For the Diagnostics & Research subindustry, Proteome Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences's Enterprise Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Proteome Sciences's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences (FRA:PI2) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Proteome Sciences's current Enterprise Value is €25.17 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Proteome Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-2.80 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Proteome Sciences's current Enterprise Value is €25.17 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Proteome Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.80 Mil.
Proteome Sciences's current Enterprise Value is €25.17 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Proteome Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €5.84 Mil.
Proteome Sciences's current Enterprise Value is €25.17 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Proteome Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of Proteome Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Proteome Sciences PLC is protein biomarker research and development. provider of contract research services for the identification, validation and application of protein biomarkers. Its only reportable segment is the sale of goods and biomarker services. It generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Other.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:PI2 has been successfully added to your 